Nargess Farhangdoost

Nargess Farhangdoost

Auto-generated profile, based on publicly available information

Nargess Farhangdoost

Department of Human Genetics, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cell Reports
Verified
Journal Article
Open access
NFNargess Farhangdoost
Nargess Farhangdoost
CHCynthia Horth
Cynthia Horth
BHBo Hu
Bo Hu
EBEric Bareke
Eric Bareke
XCXiao Chen
Xiao Chen
JMJacek Majewski
Jacek Majewski
Chromatin dysregulation has emerged as an important mechanism of oncogenesis. To develop targeted treatments, it is important to understand the transcriptomic consequences of mutations in chromatin modifier genes. Recently, mutations in the histone methyltransferase gene nuclear receptor binding SET domain protein 1 (NSD1) have been identified in a subset of common and deadly head and neck squamous cell carcinomas (HNSCCs). Here, we use genome-wide approaches and genome editing to dissect the downstream effects of loss of NSD1 in HNSCC. We demonstrate that NSD1 mutations are responsible for loss of intergenic H3K36me2 domains, followed by loss of DNA methylation and gain of H3K27me3 in the affected genomic regions. In addition, those regions are enriched in cis-regulatory elements, and subsequent loss of H3K27ac correlates with reduced expression of their target genes. Our analysis identifies genes and pathways affected by the loss of NSD1 and paves the way to further understanding the interplay among chromatin modifications in cancer.

2 May 2025 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
NFNargess Farhangdoost
Nargess Farhangdoost
CLCalwing Liao
Calwing Liao
YLYumin Liu
Yumin Liu
DRDaniel Rochefort
Daniel Rochefort
FAFarah Aboasali
Farah Aboasali
GRGuy A Rouleau
Guy A Rouleau

15 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NFNargess Farhangdoost
Nargess Farhangdoost
CLCalwing Liao
Calwing Liao
YLYumin Liu
Yumin Liu
MAMartin Alda
Martin Alda
PDPatrick A. Dion
Patrick A. Dion
BCBoris Chaumette
Boris Chaumette
The gene A-kinase anchoring protein 11 ( AKAP11 ) recently emerged as a shared risk factor between bipolar disorder and schizophrenia, driven by large-effect loss-of-function (LoF) variants. Recent research has uncovered the neurophysiological characteristics and synapse proteomics profile of Akap11 -mutant mouse models. Considering the role of AKAP11 in binding cAMP-dependent protein kinase A (PKA) and mediating phosphorylation of numerous substrates, such as transcription factors and epigenetic regulators, and given that chromatin alterations have been implicated in the brains of patients with bipolar disorder and schizophrenia, it is crucial to uncover the transcriptomic and chromatin dysregulations following the heterozygous knockout of AKAP11 , particularly in human neurons. In this study, we use genome-wide approaches to investigate such aberrations in human induced pluripotent stem cell (iPSC)-derived neurons. We show the impact of heterozygous AKAP11 LoF mutations on the gene expression landscape and profile the methylomic and acetylomic modifications. Altogether we highlight the involvement of aberrant activity of intergenic and intronic enhancers, which are enriched in PBX homeobox 2 (PBX2) and Nuclear Factor-1 (NF1) known binding motifs, respectively, in transcription dysregulations of genes functioning as DNA-binding transcription factors, actin and cytoskeleton regulators, and cytokine receptors, as well as genes involved in G-protein-coupled receptors (GPCRs) binding and signaling. A better understanding of the dysregulations resulting from haploinsufficiency in AKAP11 improves our knowledge of the biological roots and pathophysiology of BD and SCZ, paving the way for better therapeutic approaches.

28 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NFNargess Farhangdoost
Nargess Farhangdoost
APAlessia Pietrantonio
Alessia Pietrantonio
YLYumin Liu
Yumin Liu
CLCalwing Liao
Calwing Liao
DRDaniel Rochefort
Daniel Rochefort
GRGuy A Rouleau
Guy A Rouleau
Bipolar disorder (BD) is a complex psychiatric condition usually requiring long-term treatment. Lithium (Li) remains the most effective mood stabilizer for BD, yet it benefits only a subset of patients, and its precise mechanism of action remains elusive. Exome sequencing has identified AKAP11 (A-kinase anchoring protein 11) as a shared risk gene for BD and schizophrenia (SCZ). Given that both the AKAP11-Protein Kinase A (PKA) complex and Li target and inhibit Glycogen Synthase Kinase-3 beta (GSK3β), we hypothesize that Li may partially normalize the transcriptomic and/or epigenomic alterations observed in heterozygous AKAP11 -knockout (Het- AKAP11 -KO) iPSC-derived neurons. In this study, we employed genome-wide approaches to assess the effects of Li on the transcriptome and epigenome of human iPSC-derived Het- AKAP11 -KO neuronal culture. We show that chronic Li treatment in this cellular model upregulates key pathways that were initially downregulated by Het- AKAP11 -KO, several of which have also been reported as downregulated in synapses of BD and SCZ post-mortem brain tissues. Moreover, we demonstrated that Li treatment partially rescues certain transcriptomic alterations resulting from Het- AKAP11 -KO, bringing them closer to the WT state. We suggest two possible mechanisms underlying these transcriptomic effects: (1) Li modulates histone H3K27ac levels at intergenic and intronic enhancers, influencing enhancer activity and transcription factor binding, and (2) Li enhances GSK3β serine 9 phosphorylation, impacting WNT/β-catenin signaling and downstream transcription. These findings underscore Li’s potential as a therapeutic agent for BD and SCZ patients carrying AKAP11 loss-of-function variants or exhibiting similar pathway alterations to those observed in Het- AKAP11 -KO models.